Literature DB >> 21713397

Reirradiation of spinal column metastases: comparison of several treatment techniques and dosimetric validation for the use of VMAT.

Florian Stieler1, Dirk Wolff, Linda Bauer, Hans-Jörg Wertz, Frederik Wenz, Frank Lohr.   

Abstract

BACKGROUND: For reirradiation of spinal column metastases, intensity-modulated radiation therapy (IMRT) reduces the dose to the spinal cord, while allowing longer treatment times. We analyzed the potential of volumetric modulated arc therapy (VMAT) to reduce treatment time and number of monitor units (MU). PATIENTS AND METHODS: In CT datasets of 9 patients with spinal column metastases, the planned target volume (PTV) encompassed the macroscopic tumor including the spinal cord or medullary cone, respectively. The prescribed dose for the target was 40 Gy, but median spinal cord dose was intended to be < 26 Gy. We compared a posterior (3D-PA) static field technique, a two-field wedge technique (3D-wedge) and 5-/7-beam IMRT with VMAT. Conformity index (CI), homogeneity index (HI40), dose volume histogram (DVH) parameters, treatments delivery time (T), and MU were analyzed. Dosimetry was validated with EDR2-film/ionization chambers.
RESULTS: PTV coverage was insufficient for 3D-conformal radiotherapy (3D-CRT) when spinal cord tolerance was respected. The IMRT approach provided excellent results but has the longest treatment time. VMAT produced dose distributions similar to IMRT with shorter treatment times (VMAT: mean 4:49 min; IMRT: mean 6:50 min) and fewer MU (VMAT: 785; IMRT: 860). Reduced conformity and increased homogeneity for VMAT when compared to IMRT were observed. An absolute deviation between measured and calculated dose of +0.70 ± 3.69% was recorded. γ-Index analysis showed an agreement of 91.33 ± 3.53% for the 5%/5 mm criteria.
CONCLUSION: For this paradigm, VMAT produces high quality treatment plans with homogeneity/conformity similar to static IMRT, shorter treatment times, and fewer MU. Verification measurements showed good agreement between calculation and delivered dose, leading to clinical implementation.

Entities:  

Mesh:

Year:  2011        PMID: 21713397     DOI: 10.1007/s00066-011-2198-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  23 in total

1.  Long-term results of fractionated strontium-90 radiation therapy for pterygia.

Authors:  Y Nishimura; A Nakai; T Yoshimasu; Y Yagyu; K Nakamatsu; H Shindo; O Ishida
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

Review 2.  Postoperative irradiation of pterygium with 90Sr eye applicator.

Authors:  S Fukushima; T Inoue; T Inoue; S Ozeki
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

3.  Postoperative irradiation of primary or recurrent pterygium: results and sequelae.

Authors:  I Monteiro-Grillo; L Gaspar; M Monteiro-Grillo; F Pires; J M Ribeiro da Silva
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

4.  Comparative efficacy of beta-irradiation and mitomycin-C in primary and recurrent pterygium.

Authors:  T Simşek; I Günalp; H Atilla
Journal:  Eur J Ophthalmol       Date:  2001 Apr-Jun       Impact factor: 2.597

Review 5.  Prevention of pterygium recurrence by postoperative single-dose beta-irradiation: a prospective randomized clinical double-blind trial.

Authors:  Ina M Jürgenliemk-Schulz; Lidy J C Hartman; Judith M Roesink; Robbert J H A Tersteeg; Ingeborg van Der Tweel; Henk B Kal; Maarten P Mourits; Harm K Wyrdeman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-07-15       Impact factor: 7.038

6.  Postoperative beta irradiation for control of pterygium.

Authors:  R A Smith; S A Dzugan; P Kosko
Journal:  J Miss State Med Assoc       Date:  2001-06

7.  Prospective study of exclusive strontium-/yttrium-90 beta-irradiation of primary and recurrent pterygia with no prior surgical excision. Clinical outcome of long-term follow-up.

Authors:  Iraklis Vastardis; Bojan Pajic; Richard H Greiner; Brigitte Pajic-Eggspuehler; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2009-12       Impact factor: 3.621

8.  Postoperative pterygium prevention by radiotherapy with strontium-90 beta-rays.

Authors:  F Pajonk; H Flick; H Mittelviefhaus; J Slanina
Journal:  Front Radiat Ther Oncol       Date:  1997

9.  5-fluorouracil vs. beta-irradiation in the prevention of pterygium recurrence.

Authors:  C O Bekibele; A M Baiyeroju; B G K Ajayi
Journal:  Int J Clin Pract       Date:  2004-10       Impact factor: 2.503

10.  Prospective study on exclusive, nonsurgical strontium-/yttrium-90 irradiation of pterygia.

Authors:  Bojan Pajic; Andreas Pallas; Daniel Aebersold; Guenther Gruber; Richard H Greiner
Journal:  Strahlenther Onkol       Date:  2004-08       Impact factor: 3.621

View more
  19 in total

1.  RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma.

Authors:  G Z Gong; Y Yin; L G Xing; Y J Guo; T Liu; J Chen; J Lu; C Ma; T Sun; T Bai; G Zhang; R Wang
Journal:  Strahlenther Onkol       Date:  2012-02-08       Impact factor: 3.621

2.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

3.  Metastatic spinal cord compression in non-small cell lung cancer patients. Prognostic factors in a series of 356 patients.

Authors:  D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-02-25       Impact factor: 3.621

4.  Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost.

Authors:  Y K Lee; J L Bedford; H A McNair; M A Hawkins
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

5.  Metastatic spinal cord compression in patients with cancer of unknown primary. Estimating the survival prognosis with a validated score.

Authors:  S Douglas; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2012-09-29       Impact factor: 3.621

6.  Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression?

Authors:  D Rades; S Huttenlocher; J N Evers; A Bajrovic; J H Karstens; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-02-16       Impact factor: 3.621

7.  Quasi-VMAT in high-grade glioma radiation therapy.

Authors:  G Fadda; G Massazza; S Zucca; S Durzu; G Meleddu; M Possanzini; P Farace
Journal:  Strahlenther Onkol       Date:  2013-04-04       Impact factor: 3.621

8.  Prognostic factors for local control and survival in patients with spinal cord compression from myeloma.

Authors:  D Rades; S Douglas; T Veninga; P Poortmans; A Bajrovic; P J Hoskin; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-03-14       Impact factor: 3.621

9.  A survival score for patients with metastatic spinal cord compression from prostate cancer.

Authors:  D Rades; S Douglas; T Veninga; A Bajrovic; L J A Stalpers; P J Hoskin; V Rudat; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-04-25       Impact factor: 3.621

10.  Optimization by visualization of indices.

Authors:  Uwe Haverkamp; Darius Norkus; Jan Kriz; Mariam Müller Minai; Franz-Josef Prott; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2014-06-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.